CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages

Table 3

SN, SP, PPV, and NPV of CA125, HE4, ROMA, and CPH-I in differentiating BOT I+II from EOC I+II group stratification by different menopausal statuses.

Menopausal status	SN (%)	SP (%)	PPV (%)	NPV (%)
All
HE4	65.74	84.03	75.53	76.58
CA125	55.56	81.25	68.97	70.91
ROMA	62.96	88.19	46.45	75.61
CPH-I	78.7	74.31	69.70	82.30
Pre-M
HE4	73.77	66.39	64.00	78.20
CA125	54.1	82.79	61.11	78.29
ROMA	78.69	64.75	63.23	85.71
CPH-I	70.49	78.69	62.30	84.20
Post-M
HE4	70.21	90.91	88.64	68.00
CA125	76.6	63.64	81.82	44.44
ROMA	82.98	68.18	73.21	53.85
CPH-I	85.11	68.18	85.10	68.20

Abbreviations: SN = sensitivity; SP = specificity; PPV = positive predictive value; NPV = negative predictive value; Pre-M = premenopausal; Post-M = postmenopausal; BOT I+II = borderline ovarian tumors in FIGO stages I and II; EOC I+II = epithelial ovarian cancer in FIGO stages I and II.